Deals
Gilead Paid $3.15B for Tubulis; TUB-040 Posts 61% ORR
Gilead's $3.15B Tubulis bet just got its first public data read: TUB-040 hit 61% response where standard care manages five months.
Deals — Page 3
M&A, fundraising, IPOs, and bankruptcies in regulated industries.
Deals
Raised $65B, Anthropic Tops OpenAI at $965B
Anthropic's Series H puts its valuation at $965 billion, a 154% step-up from February, with an investor list that reads like an IPO roadshow roster.
Deals
Pfizer Buys 12-Drug China Cancer Portfolio for $650M
Pfizer's $650M entry into China's early oncology machine mirrors BMS-Hengrui by two weeks, and neither buyer has Phase 1 data to show for it.
Deals
Groq Raises $650M for Neocloud After Nvidia Deal
Groq licensed its chip IP to Nvidia for $20B and lost its founding team. Now the remnant is raising $650M for a neocloud second act.
Deals
IBM, Red Hat Commit $5B to Open Source Security
IBM bet $5B and 20,000 engineers on enterprises paying for secured open source, with Goldman Sachs, JPMorganChase, and nine other banks already in.
Deals
Apogee Sold $1.3B in Royalties, Shares -11%
Apogee's $1.3B Blackstone royalty deal crushed M&A hopes and sent shares -11%, even as zumilokibart's Phase 2 data matched Lilly's Ebglyss.
Deals
Loses Two: Goldman Sheds C-Suite Pair in June
Goldman's chief of staff is out in June, making two management committee exits this year — the second shadowed by the Epstein fallout.
Deals
Uber Mulls Higher Delivery Hero Bid After €38 Snub
Uber's board is weighing whether to top €38 a share for Delivery Hero as DoorDash circles. A key shareholder has already said no twice.
Deals
Mastercard Bills Processors Half of $997M Brazil Loss
Mastercard paid half of Brazil's $997M Will Bank tab and wants processors to cover the rest. Cielo says acquirers never owned the risk.
Deals
Filed: CVC, GBL Bid €10.7B to Delist Recordati
CVC and GBL bid €10.7B to take Recordati private, but a 13% premium to the March price is a thin ask when you already control the register.
Deals
EU Reviews MiCA Two Years In; Dollar Stablecoins Win
Europe's flagship crypto framework is barely two years old, and Brussels is already asking if it can survive dollar stablecoins' global grip.
Deals
Lilly Bought Engage Bio's DNA Platform for $202M
Eli Lilly paid up to $202M for a preclinical biotech with zero disclosed programs: the platform bet driving its $21B 2026 buying spree.
Deals
Immunovant Paid $39M to Exit Batoclimab After TED Fails
Immunovant paid $39M in exit costs on batoclimab after two phase 3 TED trial failures, while next-gen IMVT-1402 RA data lifted shares 20%.
Deals
Oorja Bio Banks $30M on IPF Drug ORJ-001
Acceleron veterans bet Westlake BioPartners' $30M on ORJ-001, a first-in-class IPF peptide with Phase 1 data in hand and Phase 2 next.
Deals
Commure Raises $70M at $7B, Targets $1T Market
Commure raised $70M at a $7B valuation, with General Catalyst doubling down on AI that automates 85% of hospital billing without human hands.
Deals
Regeneron Commits $125M Upfront in $2.3B Parabilis Deal
Regeneron pays $125M upfront in a $2.3B Parabilis collaboration to build antibody-helicon conjugates, a drug class that doesn't exist yet.
Deals
Boston Scientific buys into MiRus for up to $4.5B
Boston Scientific paid $1.5B for 34% of MiRus and locked in a $3B option for its SIEGEL TAVR system, one year after scrapping its own valve program.
Deals
Pfeifer Exits AC Immune
Andrea Pfeifer ends her run at AC Immune, sending the company into its first-ever CEO search.
Deals
equipifi Raises $34M to Build Bank BNPL
Left Lane Capital's $34M Series B in equipifi targets the 49% of credit union members already routing BNPL through outside providers.
Deals
Bought for $500M, Intermex Faces NYC Regulatory Block
NYC Mayor Mamdani is asking regulators to kill Western Union's $500M Intermex buy, citing fee hikes that would hit immigrant families hardest.
